Amphastar Pharmaceuticals, Inc. (AMPH) Form 8-K — Jul 13, 2026
Amphastar Pharmaceuticals appointed Anthony Pierce as a new Class III director effective July 9, 2026, increasing the Board's authorized size from ten to eleven members. Mr. Pierce, who is classified as independent under Nasdaq listing standards, will serve until the 2028 annual meeting of stockholders.
Key figures
- Board Size
- 11
- Director Compensation Cash
- 55000
- Director Compensation Equity Value
- 300000
Price after filing
1 day: -2.5%7 days: +1.8%30 days: +5.9%
Close on the filing date to close N calendar days later (from $19.29). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.